Sign inJoin waitlistJoin the waitlist

Tatyana Feldman

Physician · Regional Cancer Care Associates LLC

Credentials: · · · · · · · ·

History

Regional Cancer Care Associates LLC
Present

Hematology and Medical Oncology
NYU Grossman School of Medicine
1999–2000
Icahn School of Medicine at Mount Sinai
1995–1999
Minsk Medical InstituteClass of
1989–1992
Doctor of Medicine
1988–1992

Research

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen…
Journal of Clinical Oncology · 2015 · 1,324 citations
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma
New England Journal of Medicine · 2018 · 633 citations
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
The Lancet · 2019 · 613 citations

Andre Goy
33 papers
Ranjana Advani
20 papers
Nancy Bartlett
18 papers
SH
Steven Horwitz
17 papers
Anthony Mato
15 papers
Lori Leslie
15 papers
Stephen Ansell
12 papers
Andrew Evens
10 papers
Andrew Ip
10 papers
Barbara Pro
10 papers
AH
Alex Herrera
9 papers
AS
Andrei Shustov
9 papers

Clinical trials

Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL
Principal investigator · Completed · Phase 1, Phase 2
Hackensack Meridian Health
2010–2015
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Site PI · Recruiting · Phase 1
Kyowa Kirin, Inc.
2026–2030
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Site PI · Recruiting · Phase 3
Corvus Pharmaceuticals, Inc.
2024–2028
Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
Site PI · Recruiting · Phase 1
SIRPant Immunotherapeutics, Inc.
2024–2025